Compare Alcon AG (ALC) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Humana Inc — how do they compare? Alcon AG trades at $73.79 (market cap $36.44B), while Humana Inc trades at $384.63 (market cap $44.77B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays the higher dividend (0.95%). Which is the better fit depends on your goals.
| ALC | HUM | |
|---|---|---|
Market Cap | $36.44B | $44.77B |
Sector | Health | Health |
52-Week High | $90.12 | $409.42 |
52-Week Low | $62.02 | $163.67 |
Enterprise Value | $40.28B | $52.12B |
Dividend Yield | 0.48% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
Humana (HUM) trades at $386.11, up 0.17% today, with a neutral technical outlook and mixed fundamentals. The stock shows strong revenue growth reaching $129.66B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent Q2 2026 earnings beat expectations with EPS of $7.61 versus $7.27 expected, while management focuses on Medicare Advantage margin expansion and cost reductions.
Outlook remains cautiously optimistic with a consensus price target of $409.93 offering 6% upside potential. Key opportunities include Medicare Advantage growth and operational efficiency gains, while risks involve margin pressure, regulatory changes in healthcare, and competitive threats. Analyst sentiment leans neutral with 57% hold ratings amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
